• Samedi, 19 Septembre 2020 - 21:31:29

Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus (Équipe Sabbah)

01 - Juin - 2020

Olivier Terrier, Sébastien Dilly, Andrés Pizzorno, Julien Henri, Francis Berenbaum, Bruno Lina, Bruno Fève, Frédéric Adnet, Michèle Sabbah, Manuel Rosa-Calatrava, Vincent Maréchal, Anny Slama Schwok

bioRxiv 2020

There is an urgent need for specific antiviral drugs directed against SARS-CoV-2 both to prevent the most severe forms of COVID-19 and to reduce viral excretion and subsequent virus dissemination; in the present pandemic context, drug repurposing is a priority. Targeting the nucleoprotein N of the SARS-CoV-2 coronavirus in order to inhibit its association with viral RNA could be a strategy to impeding viral replication and possibly other essential functions associated with viral N. The antiviral properties of naproxen, belonging to the NSAID family, previously demonstrated against Influenza A virus, were evaluated against SARS-CoV-2. Naproxen binding to the nucleoprotein of SARS-CoV2 was shown by molecular modeling. In VeroE6 cells and reconstituted human primary respiratory epithelium models of SARS-CoV-2 infection, naproxen inhibited viral replication and protected the bronchial epithelia against SARS-CoV-2 induced- damage. The benefit of naproxen addition to the standard of care is tested in an on-going clinical study.

Structural comparison of viral nucleoproteins N:

Terreir et al 2020.jpg

Centre de Recherche
UMR_S 938

Hôpital St-Antoine


Tél : +(33) 1 49 28 46 00